NDAORALTABLET
Approved
Jul 2014
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
4/8 — Partial
ACTICLATE (doxycycline hyclate) by Molecular Devices is 12. First approved in 2014.
Drug data last refreshed 18h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ACTICLATE (doxycycline hyclate) is an oral tetracycline-class antimicrobial that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. It is indicated for treatment of various bacterial infections across multiple organ systems. The drug demonstrates oral bioavailability with peak plasma levels at 3 hours and a serum half-life of 18-22 hours, independent of renal function.
Peak
Product is at peak lifecycle stage with moderate competitive pressure (30%), suggesting stable team size and mature commercial operations without significant growth investment.
Mechanism of Action
12.1 Mechanism of Action Doxycycline is a tetracycline-class antimicrobial drug [see ] . 12.3 Pharmacokinetics Absorption Doxycycline hyclate tablets: Following administration of a single 300 mg dose to adult volunteers, average peak plasma doxycycline levels were 3.0 mcg per mL at 3 hours,…
Worked on ACTICLATE at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.